SA515361061B1 - مجالات سيطرة جاما- حمض كربوكسي جلوتاميك كعوامل استهدافية - Google Patents
مجالات سيطرة جاما- حمض كربوكسي جلوتاميك كعوامل استهدافية Download PDFInfo
- Publication number
- SA515361061B1 SA515361061B1 SA515361061A SA515361061A SA515361061B1 SA 515361061 B1 SA515361061 B1 SA 515361061B1 SA 515361061 A SA515361061 A SA 515361061A SA 515361061 A SA515361061 A SA 515361061A SA 515361061 B1 SA515361061 B1 SA 515361061B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- cancer
- yeah
- polypeptide
- gla
- annexin
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 28
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 108090000672 Annexin A5 Proteins 0.000 claims description 5
- 102000004121 Annexin A5 Human genes 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 230000001640 apoptogenic effect Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 102000000412 Annexin Human genes 0.000 claims 3
- 108050008874 Annexin Proteins 0.000 claims 3
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 2
- JIGWWGDIEUWCOR-UHFFFAOYSA-N 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-fluorodibenzothiophene 5,5-dioxide Chemical compound C1=C2S(=O)(=O)C=3C(F)=CC=CC=3C2=CC=C1N1CCN2CCC1CC2 JIGWWGDIEUWCOR-UHFFFAOYSA-N 0.000 claims 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 claims 1
- 101150082527 ALAD gene Proteins 0.000 claims 1
- 241001093575 Alma Species 0.000 claims 1
- 101100152881 Arabidopsis thaliana THAL gene Proteins 0.000 claims 1
- 101100001231 Caenorhabditis elegans aha-1 gene Proteins 0.000 claims 1
- 240000005589 Calophyllum inophyllum Species 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 241001649081 Dina Species 0.000 claims 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 102100039554 Galectin-8 Human genes 0.000 claims 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 claims 1
- 101000887168 Gallus gallus Gallinacin-8 Proteins 0.000 claims 1
- 241000782222 Khadia Species 0.000 claims 1
- 241000282838 Lama Species 0.000 claims 1
- 244000062939 Leptospermum ericoides Species 0.000 claims 1
- 235000017763 Leptospermum ericoides Nutrition 0.000 claims 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 claims 1
- 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 claims 1
- 241000549435 Pria Species 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 241000405965 Scomberomorus brasiliensis Species 0.000 claims 1
- 239000004268 Sodium erythorbin Substances 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract description 13
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract description 12
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 210000000170 cell membrane Anatomy 0.000 description 9
- 108090000190 Thrombin Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 101100463573 Komagataella pastoris PEX6 gene Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 101100519629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX2 gene Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
Abstract
يتعلق الكشف الحالي ببروتينات مجال سيطرة لحمض جاما- كربوكسي جلوتاميك Gla (gamma-carboxyglutamic-acid) واستخدامها لاستهداف أجزاء فوسفاتيديل سرين phosphatidylserine (PtdS) على أسطح الخلايا، تحديدا تلك التي تظهر مستويات مرتفعة من PtdS (phosphatidylserine)، مثل الخلايا الخاضعة للاستماتة. يمكن أن تتصل البروتينات مع كل من الأحمال التشخيصية والعلاجية، علاج يسمح بتحديد ومعالجة خلايا إظهار PtdS (phosphatidylserine) زائد. شكل(1)
Description
١ مجالات سيطرة جاما- حمض كريوكسي جلوتاميك كعوامل استهدافية
Gla domains as targeting agents الوصف الكامل خلفية الاختراع يتعلق الكشف الحالي باستهداف فوسفاتيديل سرين (PtdS) (phosphatidylserine) على أغشية خلية باستخدام ببتيدات (peptides) وعديد ببتيدات (polypeptides) مجال السيطرة لحمض جاما- كريوكسي جلوتاميك (Gla) gamma-carboxyglutamic—acid يتم الكشف عن استخدام تلك الببتيدات وعديد الببتيدات كعوامل علاجية وتشخيصية. إن فوسفاتيديل سرين (PtdS) (phosphatidylserine) هو مكون دهن الفوسفوري أو الليبيدات المفسفرة phospholipid مشحون بصورة سالبة متموضع sale على gall الورقي الشكل الداخلي (الجانب السيتويلازمي (cytoplasmic side من غشاء الخلية. مع هذاء يمكن نقل فوسفاتيديل سرين (PtdS) (phosphatidylserine) بواسطة gmc) scramblase من عائلة فليباز (flippase 0 من الجزءِ ورقي الشكل الداخلي إلى الجزءِ ورقي الشكل الخارجي ويظهر على سطح الخلية. مع Juli من الاستثناءات؛ يكون التخارج (externalization) (الميل لإدراك_ العالم الخارجي المتعلق بالذات) النشط لأجل 0105 مسئول عن التلف الخلوي ( van den Eijnde et Erwig and Henson, 2008 :2001 ,.81). على سبيل المثال؛ إصابة النسيج ترسل إشارات إلى الصفائح الدموية؛ كريات الدم البيضاء؛ والخلايا البطانية لتعيد توزيع PAS بسرعة وبصورة 5 عكسية مما يؤدي إلى تعزيز التجلط وتنشيط مكمل على أسطح الخلية. بصورة مشابهة؛ إشارات الاستماتة تتسبب في تخارج PHS على أية حال بأسلوب أكثر تدرجا ومقبول. PS الخارجي هذا يوفر علامة إدراك رئيسية تُمكن البلاعم من هضم الخلايا الميتة من النسيج المحيط ( Erwig Henson, 2008 800). عملية الإزالة هذه تكون أساسية لتوازن النسيج وتكون فعالة للغاية في بيئة 'صحية (healthy) في الحقيقة؛ على الرغم من فقد الخلايا يوميا بمقدار > OB (Av 0 الكشف الهيستولوجي عن الخلايا المستميتة يعد حدث نادر في الأنسجة السليمة ( Elitiot and Elltiot et al, 2009 ;2010 ,48/10080080). ...مع dd» هناك دليل
لاد أنه فى العديد من الحالات الباثولوجية AW (Jas أو لا توجد عملية إزالة WAY المستميتة .(Elltiot and Ravichandran, 2010; Lahorte et al., 2004) على سبيل المثال تقترح دراسات تتعلق بالأورام عديدة أن دليل الاستماتة العالى تصاحبه أورام عالية الدرجة؛ معدل متزايد للانبثاث jail ضعيف للمريض: ) ;2007 Naresh et al., 2001; Loose et al., .(Kurihara et al., 2008; Kietselaer et al., 2002 5 تلك الدراسات» ومثلها أخرى» تقترح أن الاستماتة وإظهار PAS الخارجي يمكن أن يكونا ide قوية على المرض )2010 and Ravichandran, أناااع). هناك بروتينات متنوعة بانجذابية عالية لأسطح الشحوم فوسفورية phospholipid
الأنيونية مع كون أنيكسين-/١ aug Annexin-V استخداما كمجس يستهدف PtdS
.(Lahorte et al., 2004) 0 باتجذابية عالية لأجل حويصلات تحتوي على Kd) PtdS = 5,.- V نانوجزيئي جرامي) ووزن جزيئي YY) كيلودالتون) يقع أدنى حد ترشيح الكلى (حوالي 10 كيلودالتون) أظهر Annexin-V نتائج واعدة في المجال الطبي كمجس للاستماتة ( Lin et al., Tait and Gibson, 1992 :2010). علاوة على هذاء تم استخدامه لنطاق واسع من دواعي الاستعمال المتضمنة تلك في طب alg) طب الأعصاب وطب القلب:
Lahorte et al., 2004; Boersma et al., 2005; Blankenberg, 2009; ) 15 .(Reutelingsperger et al., 2002 اتضح استخدام مجسات بيولوجية تستهدف إظهار سطح خلية 0105 في المعمل وفي الجسم الحي. Lay يكون استخدامهم في المجال الطبي واعد؛ لم يتم استغلالهم على الأغلب. الوصف العام للاختراع
20 هكذاء طبقا للكشف الحالى» تتوافر طريقة لاستهداف PAS غشاء الخلية تشتمل على (أ) توفير عديد ببتيد معزول يشمل مجال سيطرة Gla ويفتقر إلى البروتياز protease أو مجال سيطرة للارتباط بهرمون؛ و(ب) اتصال الببتيد مع سطح خلية؛ حيث يرتبط عديد الببتيد polypeptide مع 105 على غشاء الخلية. قد يكون غشاء الخلية عبارة عن غشاء خلية بالقلب؛ غشاء خلية عصبونية؛ غشاء خلية بطانية » غشاء خلية مصابة بفيروس » غشاء خلية مستميتة؛ غشاء صفائح
ا
مه
دموية أو غشاء خلية سرطان. قد يشتمل عديد الببتيد إضافيا على مجال سيطرة ارتباط عامل نمو
جلدي (epidermal growth factor) (]6ع)؛ مجال سيطرة كرنغل «Kringle و/أو مجال
سيطرة تكديس حمض أميني أروماتي 000080 aromatic amino acid stack قد يكون
مجال السيطرة Gla من العامل ell العامل VI العامل (IX العامل X بروتين 5 أو بروتين ©. قد يشتمل عديد الببتيد إضافيا على علامة قابلة للاكتشاف»؛ مثلا علامة استشعاعية؛ علامة
وميض كيميائي chemilluminescent label علامة إشعاعية «ey cradiolabel صبغة أو
مركب ترابطي Jdigand
قد يشتمل عديد الببتيد إضافيا على عامل علاجي؛ مثلا عامل مضاد للسرطان؛ يتضمن عامل
علاج كيماوي؛ عامل علاج إشعاعي؛ سيتوكين cytokine هرمون؛ جسم مضاد antibody أو
0 جزءٍ من جسم مضاد antibody fragment أو سموم 10710 أو عامل مضاد للفيروسات. قد يكون العامل العلاجي هو cal مثلا عقار أولي يحول coytokine cay) عامل نموء عامل dala أو عامل مضاد للتجلط. قد يكون عديد الببتيد عبارة عن Yoo وحدة بنائية أو ٠٠١ (Jd وجدة بنائية أو أقل؛» أو ٠٠١ وحدة بنائية أو أقل؛ تتضمن تنطاقات من ٠٠-٠٠١ و بلح وحدة بنائية.
5 .قد يشتمل عديد الببتيد على ١5-8 وحدة بنائية من ١-4 (Cla وحدة بنائية من Gla بما في ذلك فت VE OY OY NY Od AY أو ١٠١ وحدة بنائية من 8ا6. قد يشتمل عديد الببتيد على أكثر من VY وحدة بنائية من 8ا6؛ لكن dil من 77٠0 من وحدات Gla البنائية الإجمالية. قد يكون حجم عديد الببتيد بين sa ©,؛؟ Tos كيلودالتون. قد يشتمل عديد الببتيد على رابطة ثنائي سلفيد disulfide واحدة على (JY) أو 5-١ من روابط disulfide قد يشتمل
0 عديد الببتيد على مجال Gla saw بروتين 5. قد يشتمل عديد الببتيد على مجال سيطرة Gla بروتين 5 + مجال سيطرة لعاملنمو البشرة (EGF) epidermal growth factor بروتين «S مجال سيطرة بروثرومبين (thrombin Gla) Gla أولي» مجال سيطرة thrombin Gla أولي + مجال سيطرة ثرومبين كرنغل thrombin Kringle أولي؛ مجال سيطرة Gla بروتين >؛ مجال Gla saws بروتين Jas + Z سيطرة thrombin Kringle أولي؛ مجال سيطرة Gla للعامل
VII 25 أو مجال سيطرة Gla للعامل VII + مجال سيطرة thrombin Kringle أولي. قد يشتمل
ge
هن
عديد الببتيد إضافيا على منطقة gall القابل للبلورة (Fc) fragment crystallizable لجسم مضاد. أي مما سبق قد يحتوي على استبدالات تحفظية للترتيبات الأصلية للبروتينات السابقة؛
و/أو يظهر نسبة تجانس مئوية مع مجالات السيطرة الأصلية المذكورة. في تجسيد آخرء تتوافر طريقة لعلاج سرطان في GIS تشمل إعطاء الكائن عديد ببتيد معزول يشمل مجال سيطرة Gla ويفتقر إلى البروتياز protease أو مجال سيطرة ارتباط بهرمون؛ حيث يتصل عيد الببتيد مع حمل علاجي. قد يكون الحمل العلاجي عبارة عن علاج كيماوي» علاج إشعاعي أو سم toxin قد يكون السرطان هو سرطان ثدي breast cancer سرطان دماغ brain cancer سرطان stomach cancer sae سرطان رئة lung cancer سرطان بروستاتا (prostate cancer سرطان مبيض ovarian cancer سرطان خصية testicular cancer 0 سرطان قولون colon cancer سرطان «skin cancer ala سرطان rectal z ill ccancer سرطان عنق الرحم ccervical cancer سرطان رحم cuterine cancer سرطان كبد dliver cancer سرطان بنكرياس cancer 080016816 سرطان الرأس والرقبة head 8 neck
.esophageal cancer أو سرطان مريء cancer في تجسيد آخر أيضاء تتوافر طريقة لعلاج مرض فيروسي في كائن تشمل إعطاء الكائن أو مجال سيطرة ارتباط protease إلى aay Gla سيطرة Jae ببتيد معزول يشمل ame 5 هرمون؛ حيث يتصل عديد الببتيد مع عامل مضاد للفيروسات. قد يكون المرض الفيروسي عبارة human immunodeficiency فيروس نقص المناعة الأدمي ¢ influenza عن الأنفلوننا فيروس «(West Nile virus فيروس غرب النيل «dengue virus فيروس الضنك virus فيروس respiratory syncytial virus الفيروس المخلوي التنفسي smallpox virus الجدري « chickenpox الجديري المائي (Korean hemorrhagic fever virus حمى النزفية الكورية 0 فيروس Epstein-Barr و؛ فيروس ١ الفيروس النطاقي الحماقي» فيروس هريس بسيط الالتهاب «yellow fever virus فيروس الحمى الصفراء chanta فيروس هنتا (Marburg human آدمي als فيروس Ebola أو ع؛ فيروس إيبولا CB ل hepatitis الكبدي فيروس الحصبة polio virus فيروس شلل الأطفال (Coxsackie فيروس papilloma virus rabies virus فيروس الكلب rubella virus فيروس الحصبة الألمانية «measles virus 5 ge
Claims (1)
- —VA- عناصر الحماية كيلودالتون يشمل: مجال حمض Te معزول بحجم من 5,5 إلى (POlypeptide) عديد ببتيد -١ ١٠-٠ من بروتين 5 به (Gla) gamma-carboxyglutamic-acid غاما كربوكسي غلوماتيك أو protease البروتياز Jae رابط من بروتين 5 وبفتقر إلى EGF مجال (Gla وحدة بنائية من المذكور مع الحمل العلاجي (polypeptide) حيث يرتبط عديد الببتيد (Oger الارتباط Jae لاستخدام في معالجة السرطان. 5 المعزول للاستخدام طبقا لعنصر الحماية )¢ حيث يشمل مجال (polypeptide) عديد الببتيد -" .١ سياق يظهر في السياق برقم التعريف: 8 يشمل متعدد Cus) المعزول للاستخدام طبقا لعنصر الحماية (polypeptide) عديد الببتيد =V 0 .1 الببتيد سياق برقم التعريف: حيث يكون الحمل ١١ المعزول للاستخدام طبقاً لعنصر الحماية (polypeptide) عديد الببتيد —¢ toxin سامة sale العلاجي المذكور هو علاج كيماوي؛ علاج إشعاعي أوحيث يكون السرطان ١١ المعزول للاستخدام طبقاً لعنصر الحماية (polypeptide) عديد الببتيد —o معدة (lay <brain cancer سرطان دماغ breast cancer oxi المذكور هو سرطان سرطان prostate cancer سرطان بروستاتا lung cancer a, سرطان ¢stomach cancer colon سرطان قولون testicular cancer ؛ سرطان خصية ovarian cancer مبيض الرحم ie سرطان rectal cancer سرطان الشرج skin cancer as سرطان «cancer 0 سرطان بنكرياس liver cancer سرطان كبد cuterine cancer سرطان رحم cervical cancer head & neck or سرطان الرأس والرقبة أو سرطان مريء (pancreatic cancer .esophageal cancer ge١ شكل 1 i 8 wi ال ا دا § i pot 35 wt. a E 3 ال ممو«3 وهم NP Maw اج x coy من ع i ml XE NMe Ww gi i= Ve lmd a إن 4م مد . 3 Sr he {ae BE SEE 2 R = NR > 5 - Hu Re BoB Hu أ 3 : اخ Ns Xm ل ا ha SR © حب Mg 8 ب SHEE ا لجخ Thal Boke oo 3 - ES SOURS TAS م 0 NCEE مك 0 سال De وق سر رع 5 = 53 & Gal 8 8 = Ped boo SEIN JI 3 SE NS 8 © | م won EE FE Co | 3 FH الي CP 51 0 5 RENE NT 3 . ool REI 3 5 Rf ل he ا ل <> RY أ أ ا ا i : الحم Pond) DW AW ed NN Ja wi POON H ERE EN 8 & 4 : “N : الح يي CIC SR EN : SRI RR 2 CNG NS eb fe 8 م 1 الما 0 صو تلواح جع“ A oo HEE a : od لا الا 8 y HR AY i . ب : |8 ما نح نا انان الب وات _ SNARE wf الحا ا [3 JAS ا 8 : 1ج اراي اليا الب الم ليا صر م 3 : 0: ra حك مان“ لماع با 8 ] : 3 3 : 3 ps TUR ue ae i : TERY 5 م ل ا ; ES NE ال i ؟ 0: LA} id ني ااا ليخ ES i : Fel] 3 FES الجخ جح ل احا مما 1 : Mio اح ال CI 8 i : يلا : ا SE FI ) هو اج اما أ اما ] H gd : Ty TEI a i الل ا ‘ 3 RE RE RR 3 . عم REE اي i ~~ pe PRESSE PL] i 1 ليم ل ا Wy ب ] os RC NAR 3 TUS ب ب PERU J A i of oe JEM كير i ot 8 بج يج كر i oF شد ا ل الما i ng ما جا خخ ماج مهم 8 KH ’ x Sa TN ب 3 + pe ada an aw a i 3 يحم JG JO TR 8 : - ؟! ةق | i wr ال . == الوم 5 8 i A أ ال EE JR 3 SHNEs oy a PEE NE 0 i WE i EN 3 IE GD ال VIN ptr را i Di Dy dn د i 11¢0A «= _ & 1 % car Ss Ns لا المت . EE 0 5 ه05 ؟ ؟ ؟ ١ لا ا ل م RA TR _ = ا لا a a 2: = = a == =Oe... AA? I = wm EE sama aE mmm ee ال ل ال ا يسيس سي ب سي ا ا ا ال Ra ا ل Ne أ اا ا ا الس11ل. 4 م ا لاد 2 owa... >= __&@=—~B_ EEE ل#لاالإإ70دد”دال”ل3ىا©ة”لا”57٠©٠©٠©ل آهالاا7 8 2 و 7و = = = EF RRR RRR ل سس سس سي 1111111 ا CEE © iE OOOO. .- CI _ = اد 4 3 Ny v His د {ola ملت لحب 9 الو oo GlasEGE 80175 5408-2147 ترتيب اشارة 00000 أولي/ بيتيد أولي ,¥ وات BOTS الات رمعم ea i aes اج عر لومي PEAKICAMY 501756 GlasE GF 70 PEAKH-OMY FVH GI Ry نم إعوعبوات ان نجاف ال افطع “ا PEAKICMY بر رتيوع Gla AV لات لفقم Fos sr عوعبوة bo § ل vo eo "0 Sia § OF gr PRARTGIV EA A PEAKB-CMVAAY ¢ بروتين ع Gla+E RF تتح او PRES on FERRER Gla od 08 PEAKE يتات افكت سن hot To. ا AN 8 نف Glaskningle J, Brombin باب-أي- شكل ؟ مي ما ا اا ا En E318 Asem Gla ا ا و a كيل ا ا ا niin EE كيني اال ا 0 we wa EE NN NEE RE ROR Re ل Te raha Na Ss اا os BNF NE ا 7 Me © ١ NL DN م so. fw ااا ا ل ا Tra aN i a RN 8 as الوه ال ا Foam ا oo Ne NE © 12 ا TT ST i و ا eRe 0 ال ا ال ات السو ا Y= = oe ae om a ل ا ل م ل ل ا د اله ا ا# pia م اد الا ا الل ااا ا 8 اال ا a , i ae gs = او ا Cha aa a TEN_.....__ § ا 0 ل 0 aE BE tenho = a a a a ء 3s Lea aa =e "££ 2 - اق oo 2 B40 ال ال ا ل eS Ny a an وا ا ا أ ل ا الس ااا اد 7 الها اا oF بين لا ... ss 0-0-0 000 ل خا 0 YE BRR SRR ER SRR RRR RRR X 8 ¥en a a ا ا اا TT ات ل 0 تت NT LT TT RRR لتم مي يدينج م BR حي يج يج عه اح جحت مش Te جد دجت TT ا اج تل ا ا ا اا ا rT. ا ا ا sss 0 ا 0 م ا Vel hoa 4 00 ٠ ميكزولتر من العينة ز ٍ 0 Yes من كريات PAGAN #إجمالية) المحمنة dina pans PEAKB-CMV BUTS a EGE ١ ترتيب اشبارة متشووضط أولي/ بينيد dl Bi 75 Gis <ٍ تسترا تضم BITE Glas BGE ¢ ات تناج 8 على pEAKTOMY TH PEAKTOMY 171777 Gla BOE IN pRAK OMY 1 بريرقين & feta GRRYEGE 7 dep pRABLOMY ¥ Helis نيكورب pEARKT-CMY A pRAKTOMY 4 بررثيق 3 صما el thromban pEAKTOMY Yo مل 1 تحت لعفم مامصمصا أرلي Gils Kringle—AY— شكل ؟ : LCL AS IER 3 ا Q سلا م = He 8 لني بيب 4348 قي ١ 3 ال ا و =~ “A ا A ا ا لك 3 x 8 ل الوا . - 8 A © الا ا TR ند اليا 31 ل od Eo hi Ci ىا © لاك اا » + SE BRE EN 2 3 & Sa 7 صم أي ا TF لا = i EC RRR 2 ! لا = 3 vy i) “Ha I SRE i 1 نا كاي ب مير 6 الل SERRA 1 0 ا 4 © لب حم Wy oF ol 4:1 mmm Sh Bea ع 4ق + الي N 4 8 ٍ ل i : i : ; a 0 33 3 1 الس لماه ا اها ١ ا : Sn EE الى & Hoy د 1 NN ب 3 3 لقن a 3 500303 RR د تآ 3 جا ل ل سي ل = wR st ا = 3 @ i i ممم 4 wn - -: 7 FH NEE FAY الا ب ا ا ا ع & 08 أ أ د الوا ا ل ا ل ل ا ERS CRSA AE | a eae 8 SH el ا ات اا ا ا جلي Rn a 4 i P31: 3a ~~ ~— 3 wr اللا حسم امي الس ب 1 اذه جد Beaman وي ال BE Cu Ba & ESR he ee 1 oe ES] 3 I SE ri “i 3 a ER ا ~ BATE & هه 8 8 2a 2a a Cy 3 Ed Bi a. HE. ERY «| B oa hv : 2 i" i 0 BI ih Emam ! 1 A A SS ASA SAA د EN ال ا 1 a wie ad OF er i RR دالء #3 IR fr ات لد CAV ل الى لأا ات {a Ee. Eh Je! % EH aia ER Mh - 0 UE 4 5 اا ا 5 يا J لب 1 > ا Lm 1 3 ¥ § ا ا ل |S & : ب ا م م NR hae WEB'S nme wos 2 > : لدم ال اا فلم I & 0 د اب معط & الاك ا ان ل ** ذه a ا ب ذال 0 هه ل ma maa Sd Sif Pree ey wo » il ب ا ل “4 Ee oy 5 = ud 2X ب ب =» 3 13 لعا Jen الف الب الها 1 yy ge o شكل م ؟” جم تو وت } } = TR OT.RQ £3 2 كر با ايض . = 1 د ب a فيا سم نج ليخ 2% - port 3 3 ا 8 T= 2 sg + ES 8 5 eee أي 7 on = 8 Ss sr 2 1 8 أ با سم © ى ل 8 بح BY oS RS = aE al EE = 0 8 5 = يمن بخ + 3 6 لأسي 52D 5 د ; ! 0 Fe oe ا ال احا نالع سر الخ سس ايخ ٍِ A = يي en 8 8 ARN ا ل ا 88 x رو ها 3 ل 5] £m em R 5 Ra 13 ب pat) = 33 hood 4 لم ©؟ 8 إل 8 GF 4 3 Boe الم ee ب ل مم لأ اس ESE 2 8 a] > ’ Fo SF em pe iB wd 8 يا 9 8 5 2 he 8 Qs = fone 4 £3 Re 7 {a 2:3 3 2 3 8 0 : Boe 8 oe 58 2 4 بم Oo ١ ها ا + 0 4 Woe Wm لقا 4 3 8 © 8 6 Fs 8 5 fod a or IS aN “wr 8 2 8 ud es ب Ea 8 ا x 3 a لخم * يخ << اب يدا لح سنا لبا ال ا {es ب i i 8 ny 3 i FR EN WR 8 ام جنا ةد اس ين باخ 8 8 “Dee انا [al ا Nit hl oH Joo BRE oe ذا Be (2 4 8 8 8 ب = i 8 8 8 a 3 5 نج 8 3 8 8 FN [SR ليخ حصي = £21 Ris wo x 3g 8 ب ا ليما نا لنب ا انبا اا ا id Bs x ad 8 4 EN 8 = 8 يخ ل wd La 3 8 hal EN 3 Na اقب 8 ; Fm EN oe EP ee BF gp We نا x so 4 pal 5 يل 8 i و Pa Rk دي iY] {ad 8 8 2 5 od 8 4 مي a XH 0 دق el 8 يد + + المي 8 = oi + ب حي : £3 oH of انا BY eer عن( ee ناد eoشكل + ب ا 4 A ا IF ملاx. ds ey FE 4 » mo BB ا ملا ييا 5 = LL i _-: متخا ف اط Es ت< [ ل#(للل”(ل-ة(ةللا] ” |”لا NE م ا ا ا ااا fa 3 و 1و ا 33 3د 1 9 قا قة £44 A 3 3 3 ¥ 3 i 3 4, 0 3 ا د - ص ", HEE © 7 .= سنا rE EEE NEE Pow دي # اس bi. NN ا ا Ea NSE A Po N 2: LB RIS ا 8 4 A ١9# 1: 3bs. Ee 3 TE a x ___________....... لك ا ل 3 13 رف8 ا ا ا © FEE 0 © ا ا ا ف 2 5 0 0 ة 4 + 4+ ةخ 4 | يي ةط & # F084 2 83 53 33 0% 0 ة eo_ A اج Y شكل 0 > < 3 FR > « تسو ة ار تباط خصو ضية جسم قضاد His awa FITC مع خلايا مستميتة Annexin-FITO يقي اس ا ا PRIA ل ا : 1 ; ] stanrosporin + fo 0 ا 0ل غير معلج 0 Has غير معالج : : 4 ب لكا قي 1 : مضخ | EIT كير من |0 ل 1 siawosposint 10 0 11 Stare + vod i إٍْ A A : 15 ا + بروتين 2 : i Foil i. { ES Pl ; § 51 4 id i ل 8 HE i ori Dd | VEO £4 : i Footy oo Pd i yg i. : I 311 3 Po yd Pod be Wo 7 il i : : ا 2 اا | H { i a Hed 3 2 ات 3 ٍْ Hho جه ا ل رما TREAD SS Sa I-AA و رديح STN EO SPIRIT SS ال م ىح لاا م أ ال لت ا ل ل اميف METI 3 Vo YX LY CNY ta LY + His-FITC مد Naren ل رض 0 5 ل ل Sama aol غير معلج Sts خخ بح ote ب يي و ع Sosa + الاسم احير رقا aOR خير Bago قد الل لبعد !لق ةلق الل ؟ة؟مآ3 . oq > Jat a i 5 > خصو صية جسم مشاد Wi تعسو سه ا َ* يب ا »> < ~ ~ 3 ال 1 + 1 Ee > Ec Ra ادا Hix ضد FITC مستميثة WA مع Apnexin-FITC «Sap برقن 1201-4 LBA gH 0201-02-4: . إٍْ : staurosporin + H + = : HH RS 1 by yl 8 mele - i : H i 1 lias حير TH غير ; ; N ب" 1 ل ا خض ا ال i : : غير معالغ. i op +بموشضاد5 1 ARG Log | Saw + FB a : SELVES pg de DOA Polen oa 1 PX 3 FI: H Haurosporiy { 8 i : : i S CMs a د : § 3 Pd i : 0# 1115 4 i PEO Pod i HE 17 Pd ا ا i I 3 io ; ا ال i ا + 31 ما { i } HI i WY Pr 1003 8ش ْ PSR OR FI : : 3 ل : ABs FS . I Ee 1: ا ا 4 1 Ci Sine ال ب i >, > 3 ARR 3 ا ا ا SNELL LR nd Vee 4 LI TE ال IS NES ١ ل ا Rg Na s Fa سوا So 1115-1116 Sm Annexin VWFITC ar wil a معالج ne NT ; San + غير Atl mle ا i a لد اغا evita خير a Tea للق ل © 0 ات ات ا ا 4ق هيا EE م_ A أ _ Crew + شكل IRs ) at >a? en Sa y ow داجما« ؟ هم 1 + يتنافس مع بروتين Annexin V ارتباط ضغيف لبروتين 5 مع كي 3 $ . > 0 0: خاي ا Te ) EN اا اي 3 اجيم معانجة 4 LA ena مز Leigh تاريل غير معالجة يساتمسنل Ri STOTT Annexin V صخ Staurosporin مع Annexin ا dk a جوع ررق 01-2 N 50011 ااا د ا 0 ميتو توخي بن جل i , ْ ب : i R ! 1 REEL 3 ; H i oD i { J LER : i 4 SEN إْ \ Poa ; ! 8 FEE : ْ 2 إٍْ i Py PLY i i ا لكر : i § 3 : 83 i i i FRE H i SR 5 + H N 8 اا د 8 i 58 3 FORE H N 3 ي“ 1 i i Poo ES A : \ SOF La i § + EER 1 1 ا 0 385 © i i 3 § fia ! i O08 LAR : N 5 3 ory i 8 3 BR IR +: : Cd PIR ل ا 3 ' N 9 Foray H 3 ra SE Nov A : ٌ 0 \ FE EY i HS SF ERY i PN H FEN : yb ad EN : 5 اسمس .ا ا SERIE J 0 NO A مب أ سن ا اس ال ا اها TTR ا .ا ا ا Hs oY 3 HIGPITC د 13-1111 Se Re 4 مل د لت ا ل لا ا اا اا لأ حي الا a ay ال ل ا قا د ae oo. a اال اكيت a BEL IR ORL ane TREE EE aE RE Ea vee Jods a يت اقب in V DO أر تباط شغيفب لير و N + يا A a 3 a 2 : د" ! S بلناقس مع بر ودين Annexin ا So 5 لبر ونين Slates إز لا ash ocr La 2 Lo $a NEY ات : ام معالجة Jurkat يتنافس أينا مرتبط مع خاديا dale غير Furkat ا سر مرحي وام يما يب No 3 Staurosporin p= Annexin V مع Co SBOE LIM EH PRA ا SHIPTON دوم د مدع عجر ; في م : 0 ] : fio ; ; a i 3 FEE 8 : ا 8 إْ iW FIN i ; PE i i fe : i | SOAR H Py 1 i § OREN i oR PoE i POF ARERR i Lod ا | i SE 8 N Pd 1 Pog i ل 0 ا i لا 0 ١ ل ا : EE RE \ vod 3 ل اخ by : SE SEE يخا i ال في اي ام ْ: i p SEY ou H د م ا H a. X Soa ; ds LoL i للستت ةل اي اس ...1 مسق . Lon BO Ni H ot 0 5 ٍ حم 8 > “% be AY ¥ x x الات ا ا S Tet re he a AN § YY LT يح مرو اا . HP LA NEE EE Hib ITC مس His- FITC حص NEN ov 0000 ا لي ا اول ا الا ال TT me TERE CTE اي MRR Basal ل يدوام Bie gg ا Jara ا الا ل eg JR SN = ا 6 © لان ا ا رق Nay La اذك رةه لقا اللي الكو كمع ته لت ةد ا ا الاك الأ ل ا SORES RR he IR iin ssn eS ns .. البغ#ة SAME rR BER sv Na eee م16مدة سريان هذه البراءة عشرون سنة من تاريخ إيداع الطلب وذلك بشرط تسديد المقابل المالي السنوي للبراءة وعدم بطلانها أو سقوطها لمخالفتها لأي من أحكام نظام براءات الاختراع والتصميمات التخطيطية للدارات المتكاملة والأصناف النباتية والنماذج الصناعية أو لائحته التنفيذية صادرة عن مدينة الملك عبدالعزيز للعلوم والتقنية ؛ مكتب البراءات السعودي ص ب TAT الرياض 57؟؟١١ ¢ المملكة العربية السعودية بريد الكتروني: patents @kacst.edu.sa
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361787753P | 2013-03-15 | 2013-03-15 | |
US201361791537P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/025940 WO2014151535A1 (en) | 2013-03-15 | 2014-03-13 | Gla domains as targeting agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SA515361061B1 true SA515361061B1 (ar) | 2019-09-22 |
Family
ID=51580982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA515361061A SA515361061B1 (ar) | 2013-03-15 | 2015-09-13 | مجالات سيطرة جاما- حمض كربوكسي جلوتاميك كعوامل استهدافية |
Country Status (25)
Country | Link |
---|---|
US (6) | US9694048B2 (ar) |
EP (5) | EP3524617B1 (ar) |
JP (4) | JP6471385B2 (ar) |
CN (2) | CN105164152B (ar) |
AU (2) | AU2014236990B2 (ar) |
BR (2) | BR112015021866A2 (ar) |
CA (3) | CA2905986A1 (ar) |
CY (2) | CY1126074T1 (ar) |
DK (4) | DK2970429T3 (ar) |
ES (4) | ES2945160T3 (ar) |
FI (2) | FI3524618T3 (ar) |
HK (2) | HK1215263A1 (ar) |
HR (2) | HRP20230527T1 (ar) |
HU (2) | HUE062021T2 (ar) |
IL (3) | IL240530B (ar) |
MX (3) | MX2015011409A (ar) |
MY (2) | MY193211A (ar) |
PE (2) | PE20152005A1 (ar) |
PL (3) | PL3524618T3 (ar) |
PT (2) | PT3524618T (ar) |
RU (3) | RU2731507C1 (ar) |
SA (1) | SA515361061B1 (ar) |
SG (3) | SG10201913166SA (ar) |
WO (2) | WO2014151683A1 (ar) |
ZA (2) | ZA201507670B (ar) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2945160T3 (es) | 2013-03-15 | 2023-06-28 | Gladiator Biosciences Inc | Dominios Gla como agentes terapéuticos |
WO2015170778A1 (ja) * | 2014-05-08 | 2015-11-12 | 学校法人日本大学 | ホスファチジルセリンの細胞表面への表出促進剤又は表出抑制剤、及び脂質ラフトのクラスター形成抑制剤 |
CN104745649B (zh) * | 2015-02-28 | 2018-03-09 | 苏州汉酶生物技术有限公司 | 一种福沙那韦中间体的生物制备方法 |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
EP3464322B1 (en) * | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Novel molecules for the treatment of inflammation |
CA3070230A1 (en) | 2017-07-24 | 2019-01-31 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
EP3679128A1 (en) * | 2017-09-05 | 2020-07-15 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
CN108159421B (zh) * | 2018-02-05 | 2021-05-18 | 苏州大学 | 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途 |
CA3091695A1 (en) * | 2018-02-20 | 2019-08-29 | Prominent Medical Inc. | Aluminum oxide surfaces and interface molecules |
MX2021004511A (es) * | 2018-10-22 | 2021-06-08 | Asahi Kasei Pharma Corp | Medicamento para el tratamiento y/o mejora de la septicemia asociada con la anomalia de la coagulacion. |
CN113061169B (zh) * | 2020-03-24 | 2022-09-27 | 江南大学 | 一种转录调控蛋白及其在共轭亚油酸生产中的应用 |
CN112057623A (zh) * | 2020-06-03 | 2020-12-11 | 江苏靶标生物医药研究所有限公司 | 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用 |
RU2768194C1 (ru) * | 2021-08-02 | 2022-03-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Нижегородский государственный технический университет им. Р.Е. Алексеева" (НГТУ) | Способ оценки степени экстернализации фосфатидилсерина на поверхность мембран эритроцитов |
AU2022376537A1 (en) * | 2021-10-29 | 2024-05-16 | Sigilon Therapeutics, Inc. | Compositions for cell-based therapies and related methods |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
WO2023192362A1 (en) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Methods of treating a subject for myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) and compositions for use in the same |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
AU1570292A (en) | 1991-02-07 | 1992-09-07 | Board Of Trustees Of The University Of Illinois, The | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
HUT71860A (en) | 1992-08-27 | 1996-02-28 | Deakin Res Ltd | Retro-, inverso-, and retro-inverso synthetic peptide analogues |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
EP0706564A1 (en) * | 1993-06-30 | 1996-04-17 | Rijksuniversiteit Leiden | Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods |
US5597457A (en) | 1995-01-23 | 1997-01-28 | The Regents Of The University Of California | System and method for forming synthetic protein crystals to determine the conformational structure by crystallography |
US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
US5929237A (en) | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
EP0965597A4 (en) * | 1996-12-27 | 2003-01-08 | Mochida Pharm Co Ltd | CELL MEMBRANE EFFECTIVE DRUGS |
US6093573A (en) | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
WO2000002587A1 (en) * | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
AU5483699A (en) | 1998-08-13 | 2000-03-06 | American Home Products Corporation | Crystal structure of escherichia coli gdp-fucose synthetase and methods of its use |
EP1108055A1 (en) | 1998-08-25 | 2001-06-20 | The Scripps Research Institute | Methods and systems for predicting protein function |
US6801860B1 (en) | 1999-02-15 | 2004-10-05 | Genetics Institute, Llc | Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
JP2002003407A (ja) | 2000-06-20 | 2002-01-09 | Medei Sci Puraningu:Kk | ハイドロキシアパタイトカルシウム指向性薬物輸送担体 |
AU2002326580A1 (en) | 2001-08-14 | 2003-03-03 | Dana-Farber Cancer Institute, Inc. | Computer-based methods of designing molecules |
AU2003298786A1 (en) * | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
BRPI0409497A (pt) * | 2003-04-18 | 2006-05-02 | Novartis Ag | métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite |
DK1644504T3 (da) * | 2003-06-19 | 2010-05-25 | Bayer Healthcare Llc | Faktor VII- eller -VIIA-Gla-domænevarianter |
EP1744734A2 (en) * | 2004-02-20 | 2007-01-24 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
US7511016B2 (en) | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
KR20070043051A (ko) | 2004-08-17 | 2007-04-24 | 쳇엘베 베링 게엠베하 | 변형된 비타민 k 의존적 폴리펩타이드 |
ES2565543T3 (es) | 2005-01-24 | 2016-04-05 | Board Of Regents, The University Of Texas System | Construcciones de fusión a Fc de unión a fosfatidilserina y su uso terapéutico |
CA2599723A1 (en) | 2005-03-04 | 2006-09-14 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
CA2625600A1 (en) | 2005-10-14 | 2007-04-26 | Biorexis Pharmaceutical Corporation | Natriuretic peptide modified transferrin fusion proteins |
US7624557B2 (en) * | 2006-05-02 | 2009-12-01 | Box Partition Technologies, Inc. | Assembling machine with continuous periodic assembly motion |
EP2147096B1 (en) * | 2007-04-13 | 2015-03-25 | Catalyst Biosciences, Inc. | Modified factor VII polypeptides and uses thereof |
KR100968839B1 (ko) * | 2008-02-25 | 2010-07-09 | 경북대학교 산학협력단 | 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도 |
WO2010006136A2 (en) * | 2008-07-09 | 2010-01-14 | Mayo Foundation For Medical Education And Research | Adenovirus targeting |
EP2311864A4 (en) * | 2008-08-13 | 2013-07-31 | Kyowa Hakko Kirin Co Ltd | RECOMBINANT PROTEIN-S COMPOSITION |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8283167B2 (en) | 2009-02-11 | 2012-10-09 | Clear Vascular Inc. | Preparation of annexin derivatives |
ES2524974T3 (es) * | 2009-06-25 | 2014-12-16 | The University Of North Carolina At Chapel Hill | Moléculas del Factor VII quimérico |
SG190450A1 (en) | 2010-12-20 | 2013-06-28 | Agency Science Tech & Res | Method of purifying exosomes |
WO2012120130A1 (en) * | 2011-03-09 | 2012-09-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods to characterize patients suffering from hemolysis |
CN103797028B (zh) | 2011-07-18 | 2017-08-25 | Iba 股份有限公司 | 使靶细胞可逆染色的方法 |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP3184121A3 (en) | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases |
US9406314B1 (en) | 2012-10-04 | 2016-08-02 | Magnecomp Corporation | Assembly of DSA suspensions using microactuators with partially cured adhesive, and DSA suspensions having PZTs with wrap-around electrodes |
ES2945160T3 (es) | 2013-03-15 | 2023-06-28 | Gladiator Biosciences Inc | Dominios Gla como agentes terapéuticos |
US9918441B2 (en) | 2015-05-14 | 2018-03-20 | J.R. Simplot Company | Potato cultivar V11 |
WO2017118764A1 (en) | 2016-01-07 | 2017-07-13 | Thomas Brocker | Novel approaches for the in vivo and in vitro visualization of dying cells |
EP3679128A1 (en) | 2017-09-05 | 2020-07-15 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
-
2014
- 2014-03-13 ES ES19160280T patent/ES2945160T3/es active Active
- 2014-03-13 SG SG10201913166SA patent/SG10201913166SA/en unknown
- 2014-03-13 MY MYPI2015703057A patent/MY193211A/en unknown
- 2014-03-13 PE PE2015001939A patent/PE20152005A1/es active IP Right Grant
- 2014-03-13 CN CN201480026243.0A patent/CN105164152B/zh active Active
- 2014-03-13 RU RU2019143609A patent/RU2731507C1/ru active
- 2014-03-13 MX MX2015011409A patent/MX2015011409A/es unknown
- 2014-03-13 CA CA2905986A patent/CA2905986A1/en active Pending
- 2014-03-13 BR BR112015021866A patent/BR112015021866A2/pt not_active Application Discontinuation
- 2014-03-13 WO PCT/US2014/026237 patent/WO2014151683A1/en active Application Filing
- 2014-03-13 PL PL19160282.0T patent/PL3524618T3/pl unknown
- 2014-03-13 FI FIEP19160282.0T patent/FI3524618T3/fi active
- 2014-03-13 ES ES14769812T patent/ES2728863T3/es active Active
- 2014-03-13 CN CN201480013636.8A patent/CN105008397B/zh active Active
- 2014-03-13 SG SG11201506307XA patent/SG11201506307XA/en unknown
- 2014-03-13 HU HUE19160282A patent/HUE062021T2/hu unknown
- 2014-03-13 EP EP19160280.4A patent/EP3524617B1/en active Active
- 2014-03-13 JP JP2016502002A patent/JP6471385B2/ja active Active
- 2014-03-13 HR HRP20230527TT patent/HRP20230527T1/hr unknown
- 2014-03-13 SG SG11201506880WA patent/SG11201506880WA/en unknown
- 2014-03-13 EP EP14770639.4A patent/EP2970429B1/en active Active
- 2014-03-13 PT PT191602820T patent/PT3524618T/pt unknown
- 2014-03-13 DK DK14770639T patent/DK2970429T3/da active
- 2014-03-13 DK DK14769812.0T patent/DK2970442T3/da active
- 2014-03-13 MY MYPI2015703136A patent/MY176901A/en unknown
- 2014-03-13 EP EP22184982.1A patent/EP4174082A1/en active Pending
- 2014-03-13 HU HUE19160280A patent/HUE062055T2/hu unknown
- 2014-03-13 PE PE2015001913A patent/PE20152020A1/es unknown
- 2014-03-13 BR BR112015021869A patent/BR112015021869A2/pt active Search and Examination
- 2014-03-13 PL PL14770639T patent/PL2970429T3/pl unknown
- 2014-03-13 FI FIEP19160280.4T patent/FI3524617T3/fi active
- 2014-03-13 AU AU2014236990A patent/AU2014236990B2/en active Active
- 2014-03-13 RU RU2015144107A patent/RU2711091C2/ru active
- 2014-03-13 CA CA3128999A patent/CA3128999C/en active Active
- 2014-03-13 WO PCT/US2014/025940 patent/WO2014151535A1/en active Application Filing
- 2014-03-13 EP EP14769812.0A patent/EP2970442B1/en active Active
- 2014-03-13 DK DK19160280.4T patent/DK3524617T3/da active
- 2014-03-13 PL PL19160280.4T patent/PL3524617T3/pl unknown
- 2014-03-13 CA CA2905972A patent/CA2905972C/en active Active
- 2014-03-13 RU RU2015144097A patent/RU2705786C2/ru active
- 2014-03-13 US US14/773,068 patent/US9694048B2/en active Active
- 2014-03-13 JP JP2016502083A patent/JP6595977B2/ja active Active
- 2014-03-13 PT PT191602804T patent/PT3524617T/pt unknown
- 2014-03-13 DK DK19160282.0T patent/DK3524618T3/da active
- 2014-03-13 ES ES19160282T patent/ES2945994T3/es active Active
- 2014-03-13 HR HRP20230632TT patent/HRP20230632T1/hr unknown
- 2014-03-13 US US14/772,971 patent/US10894075B2/en active Active
- 2014-03-13 MX MX2015011873A patent/MX2015011873A/es unknown
- 2014-03-13 EP EP19160282.0A patent/EP3524618B1/en active Active
- 2014-03-13 AU AU2014233885A patent/AU2014233885B2/en active Active
- 2014-03-13 ES ES14770639T patent/ES2756532T3/es active Active
-
2015
- 2015-08-12 IL IL24053015A patent/IL240530B/en active IP Right Grant
- 2015-08-26 IL IL240841A patent/IL240841B/en active IP Right Grant
- 2015-09-02 MX MX2021009450A patent/MX2021009450A/es unknown
- 2015-09-13 SA SA515361061A patent/SA515361061B1/ar unknown
- 2015-10-14 ZA ZA2015/07670A patent/ZA201507670B/en unknown
- 2015-10-14 ZA ZA2015/07674A patent/ZA201507674B/en unknown
-
2016
- 2016-03-18 HK HK16103167.3A patent/HK1215263A1/zh unknown
- 2016-04-25 HK HK16104677.4A patent/HK1216649A1/zh unknown
-
2017
- 2017-06-23 US US15/631,937 patent/US20170296624A1/en not_active Abandoned
-
2018
- 2018-10-25 US US16/170,131 patent/US10925926B2/en active Active
- 2018-12-27 JP JP2018244479A patent/JP6812403B2/ja active Active
-
2019
- 2019-09-27 JP JP2019176325A patent/JP2020015752A/ja not_active Withdrawn
- 2019-10-31 IL IL270353A patent/IL270353B2/en unknown
-
2020
- 2020-09-25 US US17/032,162 patent/US20210015900A1/en active Pending
- 2020-12-18 US US17/126,282 patent/US20210113657A1/en active Pending
-
2023
- 2023-06-02 CY CY20231100262T patent/CY1126074T1/el unknown
- 2023-07-04 CY CY20231100311T patent/CY1126072T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA515361061B1 (ar) | مجالات سيطرة جاما- حمض كربوكسي جلوتاميك كعوامل استهدافية | |
Bos-Mikich et al. | Platelet-rich plasma therapy and reproductive medicine | |
Straszewski-Chavez et al. | The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy | |
Bauskin et al. | Characterization of human zona pellucida glycoproteins | |
Hengartner | The biochemistry of apoptosis | |
Borges et al. | Explants of intact endometrium to model bovine innate immunity and inflammation ex vivo | |
Afkham et al. | Toll‐like receptors signaling network in pre‐eclampsia: An updated review | |
Kimoto et al. | Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U‐937 and HL‐60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. | |
Bornstein et al. | ARTS binds to a distinct domain in XIAP-BIR3 and promotes apoptosis by a mechanism that is different from other IAP-antagonists | |
Dogan et al. | Interrelationships between apoptosis and fertility in bull sperm | |
Hammerová et al. | Necroptosis modulated by autophagy is a predominant form of melanoma cell death induced by sanguilutine | |
Peng et al. | Caudatin‐2, 6‐dideoxy‐3‐O‐methy‐β‐d‐cymaropyranoside 1 induced apoptosis through caspase 3‐dependent pathway in human hepatoma cell line SMMC7721 | |
Berthelot-Ricou et al. | Assessment of 1, 2-propanediol (PrOH) genotoxicity on mouse oocytes by comet assay | |
Lee et al. | Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer | |
Anchordoquy et al. | Analysis of apoptosis and DNA damage in bovine cumulus cells after exposure in vitro to different zinc concentrations | |
Lok et al. | Microparticles of pregnant women and preeclamptic patients activate endothelial cells in the presence of monocytes | |
Johnson et al. | Cell-specific DNA fragmentation may be attenuated by a survivin-dependent mechanism after traumatic brain injury in rats | |
Gualtieri et al. | Redox control of surface protein sulphhydryls in bovine spermatozoa reversibly modulates sperm adhesion to the oviductal epithelium and capacitation | |
Soni et al. | Apoptosis and Bcl‐2 protein expression in human placenta over the course of normal pregnancy | |
Bortul et al. | Nuclear changes in necrotic HL‐60 cells | |
Zhang et al. | Correlation of epididymal protease inhibitor and fibronectin in human semen | |
Mou et al. | Male infertility-related molecules involved in sperm-oocyte fusion | |
Eini et al. | Normal seminal plasma could preserve human spermatozoa against cryopreservation damages in Oligozoospermic patients | |
Hippe et al. | Fas/CD95-mediated apoptosis of type II cells is blocked by Toxoplasma gondii primarily via interference with the mitochondrial amplification loop | |
Mohammadpour et al. | Host-derived serine protease inhibitor 6 provides granzyme B–independent protection of intestinal epithelial cells in murine graft-versus-host disease |